温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.msd.com/research/patent
点击访问原文链接

U.S. product patent information - MSD

进入原网站 导航首页
U.S. product patent information - MSD Skip to content

Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy MSD Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics and compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier registration Supplier help for Ariba Research Research overview Areas of focus Oncology Vaccines Infectious diseases Cardiovascular disease Immunology Neuroscience Ophthalmology Areas of innovation Data science and artificial intelligence Green and sustainable science Our therapeutic modalities Translational medicine Pipeline Business development and licensing Clinical Trials Clinical trials overview Diversity in clinical trials R&D locations How we invent Meet our scientists Publications Safety data sheets (SDS) Product patents Patients Patients overview Play an active role in your health care Fighting counterfeit medicine Media Media overview News releases Company statements Company fact sheet Investors Investors overview Events and presentations Stock information Careers Who we are Learn more Contact us What can we help you find? Search for: U.S. product patent information This page is intended only for residents of the U.S.
In accordance with Section 287(a) of Title 35 of the U.S. Code, the following list identifies our company’s rights in U.S. patents associated with the relevant product. This list may be a subset of our rights in U.S. patents directed to the relevant product.

Animal health Prescription pharmaceuticalsVaccines Activyl®

(indoxacarb)
U.S. Patent No. 8,475,818

BRAVECTO®

(fluralaner) chews Flavored chews for dogs
U.S. Patent No 7,662,972
U.S. Patent No 8,022,089
U.S. Patent No 8,492,311
U.S. Patent 11,285,101

BOVILIS Nasalgen 3 PMH

Live cattle vaccine
U.S. Patent No. 9,642,905
U.S. Patent No. 9,662,382

BOVILIS® Coronavirus

Live Bovine Coronavirus Vaccine
U.S. Patent No. 10,434,168 B2

BRAVECTO®

(fluralaner) topical solution dogs and cats
U.S. Patent No 7,662,972
U.S. Patent No 8,022,089
U.S. Patent No 8,492,311
U.S. Patent No. 9,532,978
U.S. Patent No. 9,173,870

BRAVECTO® Plus

(fluralaner and moxidectin) Topical Solution cats
U.S. Patent No 7,662,972
U.S. Patent No 8,022,089
U.S. Patent No 8,492,311
U.S. Patent No. 9,173,870
U.S. Patent No 9,532,978

CIRCUMVENT CML®

Porcine Circovirus Vaccine, Type 2, Killed Baculovirus Vector, Mycoplasma Hyopneumoniae
U.S. Patent No. 9,084,768 B2

FORTEGRA®

Live eimeria vaccine
U.S. Patent No. 9,050,281

INNOVAX™ ILT-IBD

Live virus poultry vaccine
U.S. Patent No. 11,596,687

INNOVAX™ ND-IBD

Live virus poultry vaccine
U.S. Patent No. 10,308,956

INNOVAX™ ND-ILT

Live virus poultry vaccine
U.S. Patent No. 8,932,604

Nobivac®: Canine Flu Bivalent

Canine influenza virus
U.S. Patent No. 7,959,929
U.S. Patent No. 9,345,758
U.S. Patent No. 8,246,962

Nobivac®: Canine Flu H3N8

Canine influenza virus
U.S. Patent No. 7,959,929
U.S. Patent No. 9,345,758

Nobivac®: Lyme

Borrelia Burgdorferi Bacterin
U.S. Patent No. 8,137,678
U.S. Patent No. 8,414,901

Nuflor Gold®

Florfenicol
U.S. Patent No. 8,034,845

Posatex® Otic Suspension

Orbifloxacin, Mometasone Furoate monohydrate and Posaconazole, Suspension
U.S. Patent No. 8,084,445
U.S. Patent No. 8,609,645

Prestige® 2

Equine influenza (EIV), equine herpesvirus type 1 (EHV-1) and equine herpesvirus type 4 (EHV-4)
U.S. Patent No. 10,555,998

Prestige® 4

Eastern and Western encephalomyelitis (EEE and WEE) viruses, equine influenza virus (EIV) and tetanus
U.S. Patent No. 10,555,998

Prestige® 5

Equine herpesvirus type 1 (EHV-1), equine herpesvirus type 4 (EHV-4), Eastern and Western encephalomyelitis (EEE and WEE) viruses, and equine influenza virus (EIV)
U.S. Patent No. 10,555,998

Prestige® V+ WNV with Havlogen®

Encephalomyelitis-Rhinopneumonitis-Influenza West Nile Virus Vaccine, Eastern and Western, Killed Virus, Killed Flavivirus Chimera, Tetanus Toxoid
U.S. Patent No. 8,048,429
U.S. Patent No. 8,133,712
U.S. Patent No. 10,555,998

Resflor Gold®

Florfenicol and Flunixin Meglumine
U.S. Patent No. 8,044,102

Zilmax®

Zilpaterol hydrochloride
U.S. Patent No. 8,580,772
U.S. Patent No. 7,207,289

Zuprevo®

Tildipirosin
U.S. Patent No. 8,227,429

BELSOMRA®

(suvorexant) Tablets
U.S. Patent No. 7,951,797
U.S. Patent No 10,098,892

BRIDION®

(sugammadex sodium injection) For intravenous use
U.S. Patent No. RE44,733

DELSTRIGO®

(doravirine/lamivudine/tenofovir disoproxil fumarate) Tablets
U.S. Patent No. 8,486,975
U.S. Patent No. 10,603,282
U.S. Patent No. 10,842,751

DIFICID®

(fidaxomicin) for Oral Suspension
U.S. Patent No. 7,863,249
U.S. Patent No. 7,378,508
U.S. Patent No. 9,808,530

DIFICID®

(fidaxomicin) Tablets for oral use
U.S. Patent No. 7,863,249
U.S. Patent No. 7,378,508

EMEND®

(aprepitant) Capsules 125/80 mg
U.S. Patent No. 8,258,132

EMEND®

(aprepitant) Capsules 40mg
U.S. Patent No. 8,258,132

EMEND®

(aprepitant) for oral suspension (125 mg)
U.S. Patent No. 8,258,132

ISENTRESS®

(raltegravir) Chewable Tablets for oral use
U.S. Patent No. 7,754,731
U.S. Patent No. 8,771,733

ISENTRESS®

(raltegravir) Film-coated Tablets for oral use
U.S. Patent No. 7,754,731
U.S. Patent No. 8,771,733

JANUMET®

(sitagliptin/metformin HCl) Tablets
U.S. Patent No. 7,326,708

JANUMET® XR

(sitagliptin and metformin HCl extended-release) Tablets
U.S. Patent No. 7,326,708

JANUVIA®

(sitagliptin) Tablets
U.S. Patent No. 7,326,708

JUVISYNC

(sitagliptin and simvastatin) Tablets
U.S. Patent No. 7,326,708

KEYTRUDA®

(pembrolizumab) For Injection
U.S. Patent No. 8,354,509
U.S. Patent No. 8,900,587
U.S. Patent No. 9,834,605
U.S. Patent No. 11,117,961
U.S. Patent No. 9,220,776

LAGEVRIO™

(molnupiravir) Capsules 200mg
U.S. Patent No. 11,331,331

PIFELTRO®

(Doravirine) Tablets
U.S. Patent No. 8,486,975

PREVYMIS®

(letermovir) injection, for intravenous use
U.S. Patent No. 8,513,255

PREVYMIS®

(letermovir) Tablets, for Oral Use
U.S. Patent No. 8,513,255

RECARBRIO®

(imipenem/cilastatin and relebactam) For intravenous use
U.S. Patent No. 8,487,093

SEGLUROMET®

(ertugliflozin and metformin) Tablets for oral use
U.S. Patent No. 8,080,580

SIVEXTRO®

(tedizolid phosphate) Powder for Infusion and Oral tablets
U.S. Patent No. 7,816,379
U.S. Patent No. 8,420,676

STEGLATRO®

(ertugliflozin) Tablets for oral use
U.S. Patent No. 8,080,580

STEGLUJAN®

(ertugliflozin and sitagliptin) Tablets for oral use
U.S. Patent No. 8,080,580

VERQUVO®

VERQUVO® (vericiguat) tablets, for oral use
U.S. Patent No. 8,420,656
U.S. Patent No. 10,736,896

WELIREG™

(belzutifan)
U.S. Patent No. 9,908,845
U.S. Patent No. RE49,948

WINREVAIR™

(sotatercept) For Injection
U.S. Patent No. 7,612,041
U.S. Patent No. 7,951,771

ZEPATIER®

(elbasvir/grazoprevir) Tablets for oral use
U.S. Patent No. 8,871,759
U.S. Patent No. 7,973,040

ZERBAXA®

(ceftolozane sulfate/tazobactam sodium) Powder for infusion
U.S. Patent No. 7,129,232

ZINPLAVA™

(bezlotoxumab) Injection, for intravenous use
U.S. Patent No. 8,257,709

ZOLINZA®

(vorinostat) Capsules
U.S. Patent No. 7,456,219
U.S. Patent No. 8,093,295

CAPVAXIVE™

PNEUMOCOCCAL 21-VALENT CONJUGATE VACCINE
U.S. Patent No. 11,116,828

ERVEBO®

EBOLA ZAIRE VACCINE, LIVE
8,012,489B2

GARDASIL®

HUMAN PAPILLOMAVIRUS QUADRIVALENT (TYPES 6, 11, 16, 18) VACCINE, RECOMBINANT
U.S. Patent No. 7,476,389

GARDASIL®9

HUMAN PAPILLOMAVIRUS 9-VALENT VACCINE, RECOMBINANT
U.S. Patent No. 7,476,389

VAXNEUVANCE®

PNEUMOCOCCAL 15 VALENT CONJUGATE VACCINE Suspension for Intramuscular Injection
U.S. Patent No. 8,192,746

Revised Date: September 2024

Related links How we invent Our teams of scientists bring together diverse expertise and background, combined with cutting-edge technologies, to help discover the next scientific breakthrough for patients. Sustainability We operate responsibly every day to enable a safe and healthy future for people and communities globally. Research We believe research is the will to conquer the impossible and that science will lead the way. Connect with us on social For patients and health care professionals MSD Manuals
Medical information source covering thousands of topics in all fields of medicine Clinical trials
Learn about our clinical trials and find available studies Sustainability Impact Report
Reporting on our commitment to operating responsibly to benefit society MSD for Mothers
An initiative to create a world where no woman has to die giving life About MSD MSD Animal Health
The global animal health business unit of MSD Contact Us
If you have a question or need more information about us, find out who you should contact. Forward-looking statementCookie policyCookie PreferencesPrivacyTerms of useAccessibilitySitemap Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

智能索引记录